ASND · NASDAQ · STOCK
Ascendis Pharma A/S
$254.27
52W $186.05 – $282.15
66/100
$15.81B
26.9
0.38
Is ASND Bullish or Bearish?
Bullish.
Innellis AI committee rates Ascendis Pharma A/S (ASND) Buy with a composite score of 66/100
, based on 6 analysts with 50% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +9.03 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -10.97 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- ROE of 129.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 134.8% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+1.00 across 1 articles, 14d) — News
Bear Case
- P/E of 27.9 is moderate-to-rich — Value
- Price-to-book of 22.5x prices in significant intangible value — Value
- Debt-to-equity of 1.93 adds balance-sheet risk to the value case — Value
- MACD histogram negative -- bearish momentum — Technical
- High leverage (debt-to-equity 1.93) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
66/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 13%
of 192 Healthcare peers
Value Analyst
neutral
45
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 129.0% shows genuine earnings power backing the valuation
− P/E of 27.9 is moderate-to-rich
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 134.8% YoY -- genuine top-line momentum
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
50
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
− High leverage (debt-to-equity 1.93) amplifies downside in a stress scenario
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
90
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+1.00 across 1 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
56.3
Neutral
MACD Histogram
-0.146
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$216.44
Resistance
$281.73
Bollinger %B
0.56
Inside Bands
Price vs Moving Averages
EMA 9
$251.76
Above
EMA 21
$252.38
Above
EMA 50
$248.83
Above
EMA 200
$227.45
Above
Fundamental Analysis
Valuation
51
Profitability
75
Financial Health
25
Cash Flow
70
Valuation
P/E Ratio
26.9×
P/B Ratio
27.84×
PEG Ratio
0.05
Dividend Yield
0.00%
52W High
$282.15
52W Low
$186.05
Quality & Growth
ROE
13458.2%
ROA
-1682.3%
Gross Margin
8817.0%
Operating Margin
-79.9%
Revenue Growth YoY
—
Debt / Equity
1.84
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 26.9 (moderate relative to a 15-40x range); Price-to-book of 27.8x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 134.6%; Return on assets of -16.8%; Net margin of 58.4%; Gross margin of 88.2%; Current ratio of 1.00 (tight short-term liquidity); Debt-to-equity of 1.84; Free cash flow per share is positive (0.68); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full ASND Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →